KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG
By Andrea Necchi, MD - Last Updated: February 18, 2023Andrea Necchi, MD, Medical Oncologist, San Raffaele Hospital and Scientific Institute, highlights the results from cohort B of the phase 2 KEYNOTE-057 trial and speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Post Tags:ASCO GU 2023-Bladder Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.